Nobel Biocare AG proposed Synthes Inc. (SYST) Chief Executive Officer Michel Orsinger as its new chairman, replacing Heino von Prondzynski. Orsinger’s appointment takes effect early next year, Nobel said in a statement on its website today. He will start attending board meetings immediately as a guest, the Glattbrugg, Switzerland-based company said. Nobel in April reported a 67-percent drop in first-quarter net income to 12.9 million euros ($19 million) and submitted a non-binding bid for AstraZeneca’s Astra Tech dental-implant business. Vice Chairman Rolf Watter will head the board on an ad-interim basis, the company said.
